LKFT

Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 29/06/2026 XAMS 14,414 25.75 371,205.18 25.60 26.00 29/06/2026 CEUX 3,399 25.74 87,478.36 25.66 26.00 29/06/2026 TQEX 696 25.71 17,897.29 25.66 26.00 29/06/2026 AQEU 916 25.71 23,551.83 25.66 25.80 30/06/2026 XAMS 19,724 26.37 520,179.08 25.98 26.74 30/06/2026 CEUX 2,068 26.45 54,694.67 26.22 26.72 30/06/2026 TQEX 508 26.53 13,478.15 26.14 26.78 30/06/2026 AQEU 445 26.09 11,610.94 26.08 26.12 01/07/2026 XAMS 20,787 26.30 546,681.47 26.06 26.48 01/07/2026 CEUX 2,613 26.20 68,467.39 26.12 26.44 01/07/2026 TQEX 71 26.40 1,874.32 26.32 26.40 01/07/2026 AQEU 198 26.17 5,181.78 26.16 26.30 02/07/2026 XAMS 13,778 26.14 360,180.34 25.88 26.54 02/07/2026 CEUX 3,021 26.06 78,727.86 25.96 26.12 02/07/2026 TQEX 115 26.23 3,015.94 25.96 26.46 02/07/2026 AQEU 721 26.12 18,835.04 25.96 26.14 03/07/2026 XAMS 15,162 26.62 403,642.76 26.46 26.86 03/07/2026 CEUX 4,786 26.59 127,266.92 26.50 26.86 03/07/2026 TQEX 526 26.75 14,071.18 26.50 26.88 03/07/2026 AQEU 74 26.62 1,970.16 26.52 26.64 Total   104,022 26.24 2,730,010.70 25.60 26.88 As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 22/06/2026 XAMS 15,297 24.59 376,162.41 24.38 24.96 23/06/2026 XAMS 15,050 25.32 381,076.53 25.06 25.52 24/06/2026 XAMS 18,944 25.55 483,992.68 25.30 25.78 25/06/2026 XAMS 17,239 25.41 438,065.40 25.12 25.72 26/06/2026 XAMS 17,000 25.22 428,748.50 24.94 25.82 Total   83,530 25.24 2,108,045.52 24.38 25.82 As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200 16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600 17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800 18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200 19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600 Total   77,667 24.6586   1,915,162.13   24.3360 25.0280 As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 38,537 Lakefront shares between June 9, 2026 and June 12, 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10-Jun-2026 ENXT 13,019 24.6037 320,315.57 24.3600 25.0800 11-Jun-2026 ENXT 12,563 24.8024 311,592.55 24.5400 24.9200 12-Jun-2026 ENXT 12,955 24.9248 322,900.78 24.8000 25.0400 Total   38,537 24.7764 954,808.90 24.3600 25.0800 As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.